Angela C. Wagoner

Angela C. Wagoner

Auto-generated profile, based on publicly available information

Angela C. Wagoner

Pre-Pivotal Drug Product Technologies, Process Development, Operations

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2025 in Molecular Pharmaceutics
Verified
Journal Article
Open access
BLBenjamin Lew
Benjamin Lew
SCSandeep Chhabra
Sandeep Chhabra
JLJacob A. Lewis
Jacob A. Lewis
AWAngela C. Wagoner
Angela C. Wagoner
AHAngel Hsu
Angel Hsu
BABrendan R. Amer
Brendan R. Amer
Lipid nanoparticles (LNPs) are an essential delivery platform for nucleic acid payloads that are susceptible to degradation or elimination. Upon administration, a biomolecular corona composed of serum proteins forms around the LNP surface, which is crucial for tissue targeting and biodistribution. One essential protein that drives the distribution of LNPs is apolipoprotein E (ApoE). In this work, we used ApoE as a model protein to probe LNP-protein interactions utilizing a surface plasmon resonance (SPR) interaction assay comparable to the conventional quartz crystal microbalance with dissipation (QCM-D) assay. We employed two LNP formulations with or without payload and various ApoE homologs to establish the SPR method as an in vitro tool to screen LNP formulations and explore species cross-reactivity in LNP-protein interactions. Two binding models were applied to capture the difference in binding behaviors of different ApoE homologs in terms of relative binding response and association kinetics.

7 July 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
DTDelia F. Tifrea
Delia F. Tifrea
WHWei He
Wei He
SPSukumar Pal
Sukumar Pal
AEAngela C. Evans
Angela C. Evans
SGSean Gilmore
Sean Gilmore
LMLuis M. de la Maza
Luis M. de la Maza
Chlamydia trachomatis is a sexually transmitted bacterium that infects over 130 million individuals worldwide annually. To implement a vaccine, we developed a cell-free co-translational system to express the Chlamydia muridarum major outer membrane protein (MOMP). This approach uses a nanolipoprotein particles (tNLP) made from ApoA1 protein, amphiphilic telodendrimer and lipids that self-assemble to form 10–25 nm discs. These tNLP provide a protein-encapsulated lipid support to solubilize and fold membrane proteins. The cell-free system co-translated MOMP and ApoA1 in the presence of telodendrimer mixed with lipids. The MOMP-tNLP complex was amenable to CpG and FSL-1 adjuvant addition. To investigate the ability of MOMP-tNLP+CpG+FSL-1 to induce protection against an intranasal (i.n.) C. muridarum challenge, female mice were vaccinated intramuscularly (i.m.) or i.n. and i.m. simultaneously 4 weeks apart. Following vaccination with MOMP-tNLP+CpG+FSL-1, mice mounted significant humoral and cell-mediated immune responses. Following the i.n. challenge, mice vaccinated with MOMP-tNLP+CpG+FSL-1 i.n. + i.m. group were protected as determined by the percentage change in body weight and by the number of C. muridarum inclusion forming units (IFU) recovered from the lungs. To our knowledge, this is the first time a MOMP-based vaccine formulated in tNLP has been shown to protect against C. muridarum.